Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I did. Can you believe it. God is great!. Got 30 contracts of May 15 $200 Puts. I'm new at options and have been following this board in the shadows. Thanks to you all for educating me.
$$VLTC $$EN*N Both Carl Icahn's investments. On the move!
$$VLTC $$ENZN Both Carl Icahn's investments. On the move!
$$VLTC $$ENZN Both Carl Icahn's investments. On the move!
$$VLTC $$ENZN Both Carl Icahn's investments. On the move!
Sour grapes!. They should look at the stock price and related appreciation.
In your dreams!
That was a great post!. LOL on the icecream comment. Hey I liked RAD's icecream cone growing up in Central California...haha. But I get your point. By the way, funny the cashier has to put on the hat before dispensing the icecream...hahahaha
APP $$$$ SHORT SQUEEZE!!!!!!!!!
APP $$$$ SHORT SQUEEZE!!!!!!!!!
Did you see what happened to RGDO? Yikes!
TXMD. Any thoughts? Why the big move today? I know about FBR's target but it sounds fluffy to me. What is going on? Thanks.
Thanks for the response. What a turd.
PVCT - Anyone know what the real story is on this one?
DD, I am bullish based on the potential the current IPCI pipeline means for the Company. The current revenues for Focalin are their for you to see and this represents a couple of quarters of sales. We all know that the current healthcare trend is towards generics from an industry perspective.
However, the one issue which I think would be a game changer for IPCI is the Rexista Abuse resistant Oxycondone. This looks to me as the wave of the future. With so much concern around the dependency and abuse of pain killers, If IPCI is successful in developing Rexista to market. Watch out.
Overall its hard to find a biotech company out there that is projected to be profitable with up to 8 ANDA's in the pipeline and a couple of in house drugs under development which currently has a market cap under $100 million. It is only a matter of time.
IPCI. I hope you guys have this one on your radars. Do some due diligence on it.
Hey guys any thoughts on RGDO? Its falling hard the past couple of weeks. REG 1 interim data analysis should be announced anytime now.
IPCI will succeed or fail based on its ability to develop and successfully market its pharmaceutical products. That is the beauty of the equity market. It will reward those companies that are successful in the LONG TERM. All else is noise.
IPCI continues to march upward. That is a fact. That is all that matters to me. I don't need to waste a moment of my life rereading anything.
I wonder who got to chase and bought at the high today. It pays to know what you own.
We have discussed time and time again that IPCI is not a "penny stock". This is a company with strong fundamentals which is there for everyone to see. Now I do not say this to imply that there are no risks but I see a great risk/reward ratio here.
Under Accrual Accounting, which is the principle used for US GAAP, Revenues are recorded (booked) when earned. Revenues are not recorded when the actual payments are received.
Dilution is sweet and looks green to me.
Look at the volume. It is going down on low volume. That should tell you all you need to know from a market perspective.
For once we agree. Smart move. To short IPCI with all that is imminent is very risky.
"run". This is not a penny stock. The stock will move up as fundamentals become clearer to the investment community. Its important to discuss IPCI in the context of NASDAQ companies instead of as some kind of penny stock.
IPCI's decision to raise money through the capital markets via an ATM is a great idea. Dilution of shares is not an issue here as increased revenues and improved profitability and outlook will more that support a higher multiple.
Captial markets exist as a source of raising funds for growth. We can all disagree with whichever method a company chooses to use to raise funds i.e., ATM or at a discount. I think it is disingenious to suggest that a public company picking a method it chooses to raise funds inorder to make capital investments which in the end enhance shareholder value somehow raises a red flag.
Congratulations!
Outstanding! post. Patient holders will be rewarded handsomely here.
Thank you for the clarification. Bottomline this is going up. I am looking forward to the Focalin sales numbers and a revaluation of marketcap due to real earnings.
Trading at $4.04 Canadian, $4.27 US. Todays conversion rate is 1.0579. Looking good and going higher. From Yahoo Finance Message board.
Right on broda...Lets ride. Folks should remember this is not a "pennystock". Do not use the same strategy as you would on a pennystock with this company. This is a Mega Monster Biopharma in the making. Patience is key here
In at average 2.18 and not selling till minimum 25. Bwahahahahahaha.
Take a look at the product pipeline and the FACT that they have just received an FDA approval, and the FACT that their partner PAR has just started shipping out products and ask yourself what happens to the stock price.
WOODCLIFF LAKE, N.J., Nov. 20, 2013 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has begun shipping dexmethylphenidate hydrochloride (HCl) 15 mg and 30 mg extended-release (ER) capsules CII following approval by the U.S. Food and Drug Administration. As marketer and distributor, Par will have 180 days of marketing exclusivity for the 15 mg strength and will share profits with its development partner.
Dexmethylphenidate HCl ER is the generic version of Novartis' Focalin XR® and is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older. According to IMS Health data, annual U.S. sales of the Focalin XR® 15 mg and 30 mg strengths are approximately $202 million.
http://www.prnewswire.com/news-releases/par-pharmaceutical-begins-shipment-of-generic-focalin-xr-capsules-232651641.html
Did you just make a negative statement on somebody's attempt at making a logical analysis of this stock and take that person's quote out of context. wow! How disingenious. You must reference the entire context of the statement. Problem with folks these days. Stop the spin
Nitwit...LOL! October 7th might as well be 2020. Frontloaders paradise if you ask me.
ALERT! TLON $1.72 FDA Approval 8/12. The Company was granted an Accelerated Approval from the FDA. If approved expect $4